Literature DB >> 3844939

Demonstration of arginyl-bradykinin moiety in rat HMW kininogen: direct evidence for liberation of bradykinin by rat glandular kallikreins.

H Kato, K Enjyoji, T Miyata, I Hayashi, S Oh-ishi, S Iwanaga.   

Abstract

The amino acid sequence around kinin moiety in rat High-Molecular-Weight (HMW) kininogen was determined by isolating a peptide containing bradykinin after cyanogen bromide treatment of the purified kininogen as follows; NH2-Thr-Ser-Val-Ile-Arg-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-Ala-Pro-Arg- Val-Lys-Lys-. The data indicated that rat HMW kininogen contains the arginyl-bradykinin moiety, instead of lysyl-bradykinin. Kinins liberated from rat HMW kininogen by rat urinary and submaxillary kallikreins were identified to be bradykinin, not arginyl-bradykinin.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3844939     DOI： 10.1016/s0006-291x(85)80157-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  17 in total

1.  Potentiation of the pro-inflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws.

Authors:  J Damas; J F Liégeois; W H Simmons
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast.

Authors:  J Wang; J Chao; L Chao
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

3.  A kallidin-like peptide is a protective cardiac kinin, released by ischaemic preconditioning of rat heart.

Authors:  Xiuxin Liu; Martina Lukasova; Radka Zubakova; Sabina Lewicka; Ulrich Hilgenfeldt
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

4.  Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.

Authors:  B A Katz; B Liu; M Barnes; E B Springman
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

5.  Design of kallidin-releasing tissue kallikrein inhibitors based on the specificities of the enzyme's binding subsites.

Authors:  F C Portaro; M H Cezari; M A Juliano; L Juliano; A R Walmsley; E S Prado
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

6.  The myostimulating effect of tissue kallikrein on rat uterus.

Authors:  J Damas; V Bourdon; J C Pinto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

7.  Kallikrein rK10-induced kinin-independent, direct activation of NO-formation and relaxation of rat isolated aortic rings.

Authors:  I Wassdal; R Hull; V P Gerskowitch; T Berg
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Specificity of S'1 and S'2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P'1 and P'2 positions in design of inhibitors.

Authors:  Daniel C Pimenta; Sandro E Fogaça; Robson L Melo; Luiz Juliano; Maria A Juliano
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

9.  Segmental expression of the bradykinin type 2 receptor in rat efferent ducts and epididymis and its role in the regulation of aquaporin 9.

Authors:  C Belleannée; N Da Silva; W W C Shum; M Marsolais; R Laprade; D Brown; S Breton
Journal:  Biol Reprod       Date:  2008-10-01       Impact factor: 4.285

10.  Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; Edwin Fink; Fred Lembeck; Bernhard A Peskar
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.